Forecast

There is no analyst data available for this company.

News Go to news feed

Enzymatica appoints Holger Lembrér as CFO

Enzymatica has appointed Holger Lembrér as its new chief financial officer; he will assume the role no later than April 2026 and will be part of the executive management. Lembrér brings extensive CFO experience from listed international companies in medtech, pharma and industry, most recently at Boule Diagnostics and previously at Oncopeptides and ASSA ABLOY. Chairman Bengt Baron highlights Lembrér’s financial expertise and international perspective to support the planned international expansion and commercial development. » More on de.investing.com

Financials

In the last quarter, Enzymatica AB had revenue of 644,93k€ and net profit of −1,17M€

(EUR)	Jun 2026	YoY
Revenue	+644,93k	13,23%
Gross profit	+292,28k	25,65%
Net profit	−1,17M	9,80%
EBITDA	−1,12M	8,53%

Fundamentals

Metric	Value
Market capitalization	+39,40M€
Number of shares	242,74M
52-week high/low	+0,31€ - +0,14€
Dividends	No
Beta	-0,4
P/E ratio	−9,71
PEG ratio	−0,50
P/B ratio	+4,45
P/S ratio	+8,41

Company profile

Enzymatica AB, ein Biowissenschaftsunternehmen, entwickelt und vertreibt Medizinprodukte für infektionsbedingte Krankheiten. Zu den Produkten des Unternehmens gehört ColdZyme Mundspray, das Erkältungen vorbeugt und die Dauer der Krankheit verkürzt. Außerdem bietet es Enzymformulierungen an. Das Unternehmen vertreibt Mundsprays unter der Marke ViruProtect in Dänemark, STADAProtect in Deutschland, Psysiomer Stop Virus in Frankreich und Zerinol Virus Defense in Italien. Enzymatica AB wurde im Jahr 2007 gegründet und hat seinen Hauptsitz in Lund, Schweden.

Name	Enzymatica AB
CEO	Sana Alajmovic
Headquarters	Lund, sn Sweden
Website	ideon.se/wp-content/uploads/ideon-images/enzymatica-ab-publ-logo-527101.jpg
Sector	Health Care
Industry	Pharmaceuticals
IPO	06/14/2011
Employees	18